A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small Cell Lung Cancer Study: (NEJ048A/NEXUS)
Akihiko Miyanaga(Nippon Medical School), Masahiro Seike(Nippon Medical School Hospital), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Takehito Shukuya(Juntendo University), Kunihiko Kobayashi(Saitama International Medical Center), Yukio Hosomi(Tokyo Metropolitan Komagome Hospital), Yukari Tsubata(Shimane University), Hajime Asahina(Hokkaido University), Shunichi Sugawara(Sendai Kousei Hospital), Satoshi Morita(Kyoto University), Kotone Matsuyama(Nippon Medical School), Tetsuya Okano, Satoshi Watanabe(Niigata University Medical and Dental Hospital)
Cited by 10
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695